newsfilter
← Latest News
GlobeNewswire·

Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies

  • Nuwellis, Inc. (NASDAQ: NUWE) received U.S. Patent No. 12,678,592 from the USPTO on July 14, 2026.
  • The patent covers the company's Dual Lumen Catheter, a device designed for extracorporeal therapies like ultrafiltration, dialysis, & continuous renal replacement therapy (CRRT).
  • The patented design features a reinforcing stainless-steel coil to prevent catheter collapse under negative pressure generated by blood pumps.
  • The catheter allows clinicians to trim the device to specific lengths for individual patients without compromising structural integrity.
  • Nuwellis states the innovation may improve blood flow, extend filter life, & offer flexibility for treating adult & pediatric patients.
  • CEO Mike McCormick highlighted the patent as a practical solution to vascular access challenges in extracorporeal therapies.
  • Nuwellis focuses on developing differentiated technologies for the heart-kidney continuum & enhancing fluid management.
  • The Aquadex SmartFlow System is indicated for continuous ultrafiltration in adult & pediatric patients weighing 20 kg or more.